Ripasudil hydrochloride hydrateGLANATEC®Glaucoma and ocular hypertensionJapan, AsiaKowa
K-321Fuchs endothelial corneal dystrophyUS, etc.Kowa
Ripasudil hydrochloride hydrate/ Brimonidine tartrateGLA-ALPHA®Glaucoma and ocular hypertensionJapanKowa
DW-1002ILM stainingEurope, US, etc.DORC
ILM stainingJapanWakamoto Pharmaceutical
ALC stainingJapan
ILM, ERM and PVR membrane stainingEurope, etc.DORC
ILM staining and ERM stainingUSDORC
DW-1001Ophthalmic treatment agentJapanROHTO Pharmaceutical
H-1337Glaucoma and ocular hypertensionUSDeveloped internally
DW-5LBTNeuropathic pain after shinglesUSJointly developed with MEDRx
DWR-2206Bullous KeratopathyJapanJointly developed with ActualEyes

Research projects

The Group is engaged in the discovery of new drug candidate compounds with a focus on protein kinase inhibitors. There are various diseases in which protein kinases are relevant, but we are promoting research with a focus on ophthalmic conditions in particular.
Leveraging our drug discovery platform technology, we are actively promoting alliances with other companies.

Our main project consists of the development of signal transmission inhibitors at our research institute (in the research facilities of Mie University) for treatment of ophthalmic, neuropathic, and respiratory conditions. In terms of joint development, we are forging ahead with multiple initiatives, such as a targeted protein degradation project with UBiENCE Inc., and an ophthalmic condition drug discovery project with RaQualia Pharma Inc..